证券代码：600976 证券简称：健民集团 公告编号：2025-017 健民药业集团股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 相关日期 本次利润分配以方案实施前的公司总股本153,398,600股为基数，每股派发现金红利0.90 元（含税），共计派发现金红利138,058,740元。 三、相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/4/29 | － | 2025/4/30 | 2025/4/30 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 4 月 15 日的2024年年度股东大会审议通过。 二、分配方案 1.发放年度：2024年年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark within the next six months [4][18]. Core Insights - The company reported a revenue of 889 million (down 8.04% year-on-year) and a net profit of 110 million (up 10.7% year-on-year) for Q1 2025, with a gross margin of 57.61% (up 15.11 percentage points) and a net margin of 12.45% (up 2.12 percentage points) [1][2]. - The decline in revenue is attributed to the ongoing optimization of the pharmaceutical commercial segment, while the increase in net profit is driven by higher revenues from the pharmaceutical industrial segment and improved product revenue structure [2]. - The company has made significant progress in cash flow, with net cash flow from operating activities increasing by 51.74% year-on-year, primarily due to increased sales collections from its pharmaceutical commercial subsidiaries [2]. Financial Performance and Forecast - The company’s revenue projections for 2025, 2026, and 2027 are 3.79 billion, 4.14 billion, and 4.56 billion respectively, with growth rates of 8%, 9%, and 10% [4][6]. - Net profit forecasts for the same years are 510 million, 650 million, and 800 million, with growth rates of 41%, 27%, and 23% [4][6]. - The report highlights a significant improvement in profitability metrics, with EPS expected to rise from 2.36 in 2024 to 5.20 in 2027 [6][12]. Strategic Initiatives - The company is reforming its marketing system to enhance performance, including implementing a profit contribution assessment alongside sales assessments, optimizing organizational structure, and advancing digitalization efforts [3]. - The company plans to accelerate the commercialization of new products in the prescription line and expand its market coverage, particularly in grassroots healthcare [3]. - The introduction of innovative traditional Chinese medicine products is expected to contribute to future revenue growth [3].

证券代码：600976 证券简称：健民集团 公告编号：2025-016 健民药业集团股份有限公司 关于小儿牛黄退热贴膏获批上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，健民药业集团股份有限公司（以下简称"公司"）从国家药品监督管 理局网站获悉，公司研发的小儿牛黄退热贴膏获批上市。现将相关情况公告如下： 一、药品获批上市的主要内容 药物名称：小儿牛黄退热贴膏 申请事项：药品注册（境内生产） 规格：每贴相当于饮片 2.4g，含薄荷脑 20mg（6cm×6cm） 注册分类：中药 1.1 类 上市许可持有人：健民药业集团股份有限公司 该药品处方源自全国名中医的临床经验方，贴于大椎穴和神阙穴，具有退热 解表、清热解毒功效，用于小儿急性上呼吸道感染风热证所致的发热(38.5℃及 以下)。该药品的上市为急性上呼吸道感染风热证所致的 1 至 5 岁发热儿童患者 提供了新的治疗选择。 二、药品研发及相关情况 药物名称：小儿牛黄退热贴膏 功能主治：退热解表，清热解毒。用于小儿急性上呼吸道感染风热证所致的 发热（38.5℃ ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's main business profits have shown a strong recovery in Q1 2025, with a non-recurring net profit of 1.03 billion yuan, representing a year-on-year increase of 13.92%. The main business profit reached 640 million yuan, up 116% year-on-year [6] - The report highlights the positive impact of the company's marketing system reform initiated in 2024, which is expected to enhance short-term profit recovery and long-term revenue growth and profitability [6] - The demand for cultured gallstones is expected to grow steadily due to an aging population and the shortage of natural gallstones, providing significant replacement opportunities [6] Summary by Sections Financial Performance - In Q1 2025, the company achieved an operating income of 892 million yuan, down 8.04% year-on-year, while the net profit attributable to shareholders was 110 million yuan, up 10.70% year-on-year [4][6] - The report forecasts revenues for 2025-2027 to be 39.50 billion yuan, 43.45 billion yuan, and 47.80 billion yuan, respectively, with net profits of 5.46 billion yuan, 6.25 billion yuan, and 7.41 billion yuan [6][8] Market Position and Growth Drivers - The company is expected to maintain high growth in its OTC and hospital sales channels, with significant market share increases for products like "Bengtong Capsule" and "Jianpi Shengxue Granule" [6] - New product launches, including pediatric and prescription drugs, are anticipated to contribute to sustained growth in the prescription line [6] Long-term Outlook - The report emphasizes the long-term growth potential of cultured gallstones, driven by increasing health demands and the aging population, which is expected to benefit downstream products containing gallstones [6]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Views - The company is positioned as a leader in pediatric traditional Chinese medicine, particularly with its flagship product, Longmu Bone Strengthening Granules, which has shown significant sales growth and market recognition [8][14]. - The company is undergoing a marketing reform and inventory management strategy, which may lead to short-term revenue decline but is expected to set a foundation for long-term growth [8][23]. - The company has a strong pipeline of innovative products and is focusing on expanding its OTC (over-the-counter) offerings, particularly in the pediatric segment [8][37]. Summary by Sections Financial Performance - The company reported a total revenue of 42.13 billion yuan in 2023, with a year-on-year growth of 15.72%. However, a decline to 35.05 billion yuan is expected in 2024, representing a decrease of 16.81% [1][23]. - The net profit attributable to shareholders for 2023 was 5.21 billion yuan, up 27.78% from the previous year, but is projected to drop to 3.62 billion yuan in 2024, a decline of 30.54% [1][23]. - The earnings per share (EPS) for 2023 was 3.40 yuan, with a forecast of 2.36 yuan for 2024 [1]. Pediatric Product Line - Longmu Bone Strengthening Granules is a leading product in the pediatric calcium supplement market, achieving sales of over 6.2 billion bags in 2023, a 15.2% increase from the previous year [8][48]. - The company is focusing on expanding its pediatric product line, which includes various formulations for common childhood ailments, and has seen a compound annual growth rate (CAGR) of 26.6% in its pediatric segment from 2018 to 2023 [8][58]. OTC Brand Development - The company is actively developing its OTC brand strategy, with a focus on products like the Bian Tong Capsule, which has seen a sales growth of 45% in 2023 [8][37]. - The pediatric drug market in China is characterized by a scarcity of suitable products, presenting significant growth opportunities for the company [8][38]. Innovation and R&D - The company has accelerated its R&D efforts, with 51 projects currently in development, including 31 new drug projects [8][33]. - Recent approvals for innovative products, such as the pediatric Zibei Syrup and the Cow Yellow Pediatric Fever Patch, are expected to enhance the company's competitive edge in the market [8][33]. Market Position and Strategy - The company maintains a strong market position in the pediatric traditional Chinese medicine sector, with a market share of 10.84% in the pediatric Chinese medicine market [8][50]. - The company is implementing strategic adjustments to its sales approach, including reducing channel inventory to better align with market demand [8][53].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司于 2025 年 4 月 8 日发出召开第十届董事会第三十 四次会议的通知，本次会议于 2025 年 4 月 18 日以通讯表决方式召开，应参与表决 的董事 9 人,实际参与表决的董事 8 人（何勤先生因身体健康原因未参与表决），符 合《公司法》和《公司章程》的规定。本次会议审议通过如下议案： 1.公司 2025 年第一季度报告 健民药业集团股份有限公司 证券代码：600976 证券简称：健民集团 公告编号：2025-015 第十届董事会第三十四次会议决议公告 健民药业集团股份有限公司 同意全资子公司健民集团叶开泰国药（随州）有限公司以自筹资金 1,133 万元 对贴膏制剂生产车间进行改造。 特此公告。 同意：8 票 弃权：1 票 反对：0 票 何勤先生因身体健康原因未能出席本次会议，亦未进行委托，视为放弃权利。 本议案经第十届董事会第十五次审计委员会审议通过，全体委员均同意该项议 案。 详 见 中 国 证 券 报 、 证 券 时 报 、 上 海 证 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥892,084,313.18, a decrease of 8.04% compared to ¥970,121,135.45 in the same period last year[4] - Net profit attributable to shareholders increased by 10.70% to ¥110,177,463.41 from ¥99,523,950.19 year-on-year[4] - The net profit after deducting non-recurring gains and losses rose by 13.92% to ¥103,066,613.51 compared to ¥90,473,671.59 in the previous year[4] - Basic and diluted earnings per share increased by 12.31% to ¥0.73 from ¥0.65 year-on-year[5] - The net profit for Q1 2025 was CNY 111,038,979.32, an increase of 10.8% compared to CNY 100,197,440.85 in Q1 2024[21] - The operating profit for the period was CNY 124,818,633.75, up from CNY 109,605,709.99 in the previous year, reflecting a growth of approximately 13.3%[21] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥24,924,066.40, an improvement of 51.74% from a net outflow of ¥51,647,096.25 in the same period last year[4] - Cash and cash equivalents as of March 31, 2025, were RMB 272,043,058.16, compared to RMB 163,173,887.90 at the end of 2024[14] - Total cash and cash equivalents at the end of Q1 2025 were CNY 263,457,096.69, slightly up from CNY 263,195,877.53 at the end of Q1 2024[26] - Investment activities generated a net cash inflow of CNY 129,265,161.41, significantly higher than CNY 44,527,721.22 in Q1 2024[25] - The total cash outflow from financing activities was CNY 66,298,284.43, which is an increase from CNY 64,523,544.01 in the previous year[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,277,683,209.72, showing a slight increase of 0.0013% from ¥4,277,629,406.13 at the end of the previous year[5] - Total liabilities decreased to RMB 1,717,304,107.60 from RMB 1,827,290,163.33, a reduction of 6.06%[16] - Total current assets amounted to RMB 2,663,539,066.72, an increase from RMB 2,601,436,202.31 at the end of 2024[15] - Accounts receivable increased to RMB 868,319,513.26 from RMB 807,667,332.99, reflecting a growth of 7.48%[15] - Total equity attributable to shareholders increased to RMB 2,545,483,050.29 from RMB 2,435,305,586.88, reflecting a growth of 4.52%[17] Operating Costs and Revenue Structure - Total operating costs for Q1 2025 were RMB 815,768,780.89, down 12.59% from RMB 932,864,246.14 in Q1 2024[20] - Operating costs included RMB 378,144,996.22 in cost of goods sold, a decrease of 32.36% from RMB 557,827,701.77 in the previous year[20] - The decline in operating revenue was primarily due to the optimization of the pharmaceutical business structure, leading to a decrease in pharmaceutical commercial income[5] - The increase in net profit was attributed to higher pharmaceutical industrial income and an improved revenue structure of leading products[5] - The company reported a net profit margin improvement due to reduced operating costs and expenses[20] Non-Recurring Gains and Future Outlook - The company reported non-recurring gains totaling ¥7,110,849.90 after tax, with significant contributions from government subsidies and other non-operating income[8] - Future outlook includes potential market expansion and new product development initiatives[20] - Research and development expenses amounted to CNY 21,006,582.52, compared to CNY 22,951,668.26 in the same quarter last year, indicating a decrease of about 8.5%[21] - The total revenue from operating activities was CNY 908,797,546.00, down from CNY 965,139,178.41 in Q1 2024, representing a decline of approximately 5.8%[24]

Group 1 - The core point of the announcement is that Jianmin Group (600976) reported a revenue of 892 million yuan for the first quarter of 2025, which represents a year-on-year decrease of 8.04% [1] - The net profit for the same period was 110 million yuan, showing a year-on-year increase of 10.70% [1]

证券代码：600976 证券简称：健民集团 公告编号：2025-014 健民药业集团股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 4 月 15 日 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，副董事长许良先生主持，会议采用现场投 票与网络投票相结合的方式进行表决，本次会议的召集、召开和表决方式符合《公 司法》及《公司章程》的有关规定。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事 9 人，出席 8 人，何勤董事长因身份健康原因未能出席； 2、公司在任监事 5 人，出席 5 人； 3、公司总裁汪俊，副总裁胡振波、黄志军、裴学军，财务总监程朝阳，董 事会秘书周捷等高级管理人员及公司见证律师出席了本次会议。 二、议案审议情况 (一)非累积投票议案 (二)股东大会召开的地点：武汉市汉阳区鹦鹉大道 484 号 ...

湖北得伟君尚律师事务所 2024 年年度股东大会的 法律意见书 二○二五年四月十五日 湖北得伟君尚律师事务所 地址：武汉市江汉区建设大道 588 号卓尔国际大厦 20 楼、21 楼 电话：（86 27 8562 0999） 电子邮箱：dewell@ dewellcn.com 湖北得伟君尚律师事务所 关于健民药业集团股份有限公司 2024 年年度股东大会的法律意见书 致：健民药业集团股份有限公司 关于健民药业集团股份有限公司 湖北得伟君尚律师事务所（以下简称本所）接受健民药业集团股份有限公司 （以下简称公司）的委托，指派律师出席公司 2024 年年度股东大会，对公司本次会 议进行见证并出具法律意见书。 本所律师依据《公司法》《上市公司股东大会规则》《上海证券交易所上市公 司股东大会网络投票实施细则》(以下简称《网络投票细则》)及《公司章程》的规 定，对公司本次会议的召集与召开程序、召集人及出席会议人员的资格、表决程序 及表决结果的合法有效性发表法律意见。 本所律师根据《证券法》《律师事务所从事证券法律业务管理办法》和《律师 事务所证券法律业务执业规则（试行）》等规定的要求，严格履行法定职责，遵循 勤勉尽责和诚实 ...